Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 72Lung Neoplasms 34Squamous Cell Carcinoma of Head and Neck 32Head and Neck Neoplasms 30Urinary Bladder Neoplasms 19Uterine Cervical Neoplasms 18Stomach Neoplasms 17Esophageal Neoplasms 17Small Cell Lung Carcinoma 16Cholangiocarcinoma 16Neoplasm Metastasis 13Ovarian Neoplasms 12Carcinoma, Squamous Cell 11Breast Neoplasms 11Neoplasms 10Mesothelioma, Malignant 9Esophageal Squamous Cell Carcinoma 8Biliary Tract Neoplasms 8Sarcoma 7Fallopian Tube Neoplasms 7Pancreatic Neoplasms 6Mesothelioma 6Adenocarcinoma of Lung 6Adenocarcinoma Of Esophagus 6Recurrence 5Gallbladder Neoplasms 5Carcinoma, Ovarian Epithelial 5Bile Duct Neoplasms 5Triple Negative Breast Neoplasms 4Osteosarcoma 4

Interventions

olaparib 1cediranib 1bomedemstat 1atezolizumab 1Platinum 1Immunoglobulin G 1Etoposide 1Disulfides 1Cisplatin 1Carboplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Extensive Stage Lung Small Cell Carcinoma × Cisplatin × Clear all
NCT02899728 2023-10-17

Olaparib, Cediranib Maleate, and Standard Chemotherapy in Treating Patients With Small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Terminated
9 enrolled 4 charts

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡